BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Inspire Pharmaceuticals, Inc. 

4222 Emperor Boulevard
Suite 200
Durham  North Carolina  27703  U.S.A.
Phone: 919-941-9777 Fax: 919-941-9797


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire’s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. The most advanced compounds in Inspire’s clinical pipeline are denufosol tetrasodium for cystic fibrosis and PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, which are both in Phase 3 development, and AZASITE® (azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye.

For more information, visit www.inspirepharm.com.


 Key Statistics


Email: info@inspirepharm.com
Ownership: Public

Web Site: Inspire Pharmaceuticals, Inc.
Employees:
Symbol: ISPH
 









 Company News
Merck & Co., Inc. (MRK) to Close Inspire Pharmaceuticals, Inc. (ISPH) Facility, 51 Jobs Axed 7/1/2011 7:23:06 AM    More...
Merck & Co., Inc. (MRK) Completes Acquisition of Inspire Pharmaceuticals, Inc. (ISPH) 5/16/2011 10:07:57 AM    More...
Merck & Co., Inc. (MRK) Announces Successful Completion of Tender Offer for Shares of Inspire Pharmaceuticals, Inc. (ISPH) With Over 75 Percent of Shares Tendered 5/13/2011 10:13:40 AM    More...
Inspire Pharmaceuticals, Inc. (ISPH) Reports First Quarter 2011 Financial Results 5/10/2011 10:31:18 AM    More...
Inspire Pharmaceuticals, Inc. (ISPH) Reports First Quarter 2011 Financial Results 5/10/2011 10:19:32 AM    More...
Merck & Co., Inc. (MRK) and Inspire Pharmaceuticals, Inc. (ISPH) Announce Expiration of Hart-Scott-Rodino Act Waiting Period Relating to Tender Offer for Shares of Inspire 4/28/2011 9:58:33 AM    More...
Inspire Pharmaceuticals, Inc. (ISPH) Postpones Annual Meeting of Stockholders Due to Recently Announced Tender Offer 4/22/2011 7:53:18 AM    More...
Inspire Pharmaceuticals, Inc. (ISPH) Announces Webcast of Presentation at Cowen and Company Health Care Conference 3/3/2011 9:32:30 AM    More...
Inspire Pharmaceuticals, Inc. (ISPH) Announces Webcast of Presentation at Citi Global Healthcare Conference 2/24/2011 10:37:22 AM    More...
Inspire Pharmaceuticals, Inc. (ISPH) Reports Fourth Quarter and Full Year 2010 Financial Results 2/17/2011 9:39:55 AM    More...
12345678910...